Cryoport Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Cryoport (NASDAQ:CYRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Cryoport's top-line revenue, earnings per share and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 88.3% of Cryoport shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Jazz Pharmaceuticals and Cryoport's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Jazz Pharmaceuticals and Cryoport, as provided by MarketBeat.

Jazz Pharmaceuticals presently has a consensus price target of $185.8824, indicating a potential upside of 15.17%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 37.69%. Given Cryoport's stronger consensus rating and higher probable upside, analysts plainly believe Cryoport is more favorable than Jazz Pharmaceuticals.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Summary

Jazz Pharmaceuticals beats Cryoport on 9 of the 14 factors compared between the two stocks.

United Therapeutics (NASDAQ:UTHR) and Cryoport (NASDAQ:CYRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares United Therapeutics and Cryoport's top-line revenue, earnings per share and valuation.

Cryoport has lower revenue, but higher earnings than United Therapeutics. Cryoport is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.1% of United Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Cryoport shares are held by institutional investors. 10.9% of United Therapeutics shares are held by company insiders. Comparatively, 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares United Therapeutics and Cryoport's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for United Therapeutics and Cryoport, as provided by MarketBeat.

United Therapeutics presently has a consensus price target of $219.5714, indicating a potential upside of 7.97%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 37.69%. Given Cryoport's higher probable upside, analysts plainly believe Cryoport is more favorable than United Therapeutics.

Volatility and Risk

United Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.

Maravai LifeSciences (NASDAQ:MRVI) and Cryoport (NASDAQ:CYRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Maravai LifeSciences and Cryoport, as provided by MarketBeat.

Maravai LifeSciences presently has a consensus price target of $38.1250, indicating a potential upside of 10.00%. Cryoport has a consensus price target of $72.00, indicating a potential upside of 37.69%. Given Cryoport's higher probable upside, analysts plainly believe Cryoport is more favorable than Maravai LifeSciences.

Valuation and Earnings

This table compares Maravai LifeSciences and Cryoport's top-line revenue, earnings per share and valuation.

Maravai LifeSciences has higher earnings, but lower revenue than Cryoport.

Institutional and Insider Ownership

88.3% of Cryoport shares are held by institutional investors. 11.5% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Maravai LifeSciences and Cryoport's net margins, return on equity and return on assets.

Cryoport (NASDAQ:CYRX) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap transportation companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Cryoport and Mirati Therapeutics, as reported by MarketBeat.com.

Cryoport presently has a consensus target price of $72.00, indicating a potential upside of 37.69%. Mirati Therapeutics has a consensus target price of $218.5714, indicating a potential upside of 28.44%. Given Cryoport's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cryoport is more favorable than Mirati Therapeutics.

Valuation & Earnings

This table compares Cryoport and Mirati Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Cryoport has higher revenue and earnings than Mirati Therapeutics. Cryoport is trading at a lower price-to-earnings ratio than Mirati Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 4.1% of Mirati Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Cryoport has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Cryoport and Mirati Therapeutics' net margins, return on equity and return on assets.

Summary

Cryoport beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap transportation companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Cryoport and BridgeBio Pharma, as reported by MarketBeat.com.

Cryoport presently has a consensus target price of $72.00, indicating a potential upside of 37.69%. BridgeBio Pharma has a consensus target price of $72.8889, indicating a potential upside of 33.77%. Given Cryoport's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cryoport is more favorable than BridgeBio Pharma.

Valuation & Earnings

This table compares Cryoport and BridgeBio Pharma's top-line revenue, earnings per share (EPS) and valuation.

Cryoport has higher earnings, but lower revenue than BridgeBio Pharma. Cryoport is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. Comparatively, 95.5% of BridgeBio Pharma shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 40.3% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Cryoport has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Profitability

This table compares Cryoport and BridgeBio Pharma's net margins, return on equity and return on assets.

Cryoport (NASDAQ:CYRX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap transportation companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Cryoport and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Cryoport presently has a consensus target price of $72.00, indicating a potential upside of 37.69%. Ultragenyx Pharmaceutical has a consensus target price of $131.20, indicating a potential upside of 26.79%. Given Cryoport's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cryoport is more favorable than Ultragenyx Pharmaceutical.

Valuation & Earnings

This table compares Cryoport and Ultragenyx Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Cryoport has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Cryoport is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.3% of Cryoport shares are owned by institutional investors. 11.5% of Cryoport shares are owned by company insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Cryoport has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.

Profitability

This table compares Cryoport and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Summary

Cryoport beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.